For US Healthcare Professionals
Over 500,000 prescriptions of the XARELTO® vascular dose* and counting1
With extensive scientific support, the XARELTO® vascular dose* redefines treatment for patients with PAD and/or CAD2-4
The FIRST and ONLY treatment approach indicated to help reduce the risks of major CV events† in patients with CAD and major thrombotic vascular events‡ in patients with PAD, including patients after recent LER due to symptomatic PAD.2
The XARELTO® vascular dose* = XARELTO® 2.5 mg twice daily plus aspirin (75 mg to 100 mg) once daily.2
Efficacy and safety demonstrated by 2 landmark clinical trials that studied ~34,000 patients with CAD and/or PAD§3,4
CAD = coronary artery disease; CV = cardiovascular, LER = lower extremity revascularization; PAD = peripheral artery disease.
*XARELTO® 2.5 mg twice daily plus aspirin (100 mg in clinical trial; 75 mg to 100 mg in practice) once daily.
†Reduction of a composite of cardiovascular death, myocardial infarction, and stroke.
‡Reduction of a composite of myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology.
§Treatment schedule: XARELTO® 2.5 mg twice daily versus placebo; all patients received aspirin 100 mg once daily as background therapy.
IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.